188 related articles for article (PubMed ID: 19747069)
1. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.
Wesnes KA; Edgar C; Tretter RN; Bolodeoku J
Expert Opin Drug Saf; 2009 Nov; 8(6):615-26. PubMed ID: 19747069
[TBL] [Abstract][Full Text] [Related]
2. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Wagg A; Dale M; Tretter R; Stow B; Compion G
Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
Kay G; Crook T; Rekeda L; Lima R; Ebinger U; Arguinzoniz M; Steel M
Eur Urol; 2006 Aug; 50(2):317-26. PubMed ID: 16687205
[TBL] [Abstract][Full Text] [Related]
5. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
Herschorn S; Vicente C; Piwko C
J Med Econ; 2010; 13(3):508-15. PubMed ID: 20690893
[TBL] [Abstract][Full Text] [Related]
6. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
8. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
[TBL] [Abstract][Full Text] [Related]
10. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
Smulders RA; Kuipers ME; Krauwinkel WJ
Br J Clin Pharmacol; 2006 Aug; 62(2):210-7. PubMed ID: 16842396
[TBL] [Abstract][Full Text] [Related]
11. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Wong C; Duggan P
J Obstet Gynaecol; 2009 Jan; 29(1):31-4. PubMed ID: 19280492
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cognitive function of the elderly population: effects of darifenacin.
Lipton RB; Kolodner K; Wesnes K
J Urol; 2005 Feb; 173(2):493-8. PubMed ID: 15643227
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers.
Kennedy DO; Jackson PA; Haskell CF; Scholey AB
Hum Psychopharmacol; 2007 Dec; 22(8):559-66. PubMed ID: 17902186
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
[TBL] [Abstract][Full Text] [Related]
15. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers.
Tildesley NT; Kennedy DO; Perry EK; Ballard CG; Wesnes KA; Scholey AB
Physiol Behav; 2005 Jan; 83(5):699-709. PubMed ID: 15639154
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of solifenacin succinate in healthy young men.
Smulders RA; Krauwinkel WJ; Swart PJ; Huang M
J Clin Pharmacol; 2004 Sep; 44(9):1023-33. PubMed ID: 15317830
[TBL] [Abstract][Full Text] [Related]
17. Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers.
Wesnes KA; Annas P; Edgar CJ; Deeprose C; Karlsten R; Philipp A; Kalliomäki J; Segerdahl M
J Psychopharmacol; 2010 Nov; 24(11):1659-69. PubMed ID: 19525335
[TBL] [Abstract][Full Text] [Related]
18. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM
Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184
[No Abstract] [Full Text] [Related]
19. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study.
Herschorn S; Pommerville P; Stothers L; Egerdie B; Gajewski J; Carlson K; Radomski S; Drutz H; Schulz J; Barkin J; Hirshberg E; Corcos J
Curr Med Res Opin; 2011 Feb; 27(2):375-82. PubMed ID: 21175373
[TBL] [Abstract][Full Text] [Related]
20. Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers.
Farber RH; Burke PJ
Curr Med Res Opin; 2008 Mar; 24(3):837-46. PubMed ID: 18257978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
